2 recruiting, 2 terminated, 1 active not recruiting, 1 completed. 3 Phase 1, 2 Phase 2, 2 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Not yet recruiting 1 |
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
| Early Phase 1 | 1 | Withdrawn 1 |
Follow arsenous acid: new trials by email Literature Review of arsenous acid trials Research Report on arsenous acid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome Allogeneic Hematopoietic Stem Cell Transplantation, Arsenic Trioxide, Biospecimen Collection - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-11-01 | 2026-07-30 |
| Arsenous Acid for Refractory Triple-Negative Breast Cancer Arsenous Acid plus Chemotherapy - Breast Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 12 | 2024-10-23 | 2025-06-06 |
| Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer Arsenic Trioxide, Itraconazole, Laboratory Biomarker Analysis - Skin Basal Cell Carcinoma | Early Phase 1 | Withdrawn | Jean Yuh Tang | 2020-12-01 | 2020-10-22 | |
| Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia Arsenic Trioxide, Cytarabine, Dexamethasone - Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA | Phase 3 | Active not recruiting | Children's Oncology Group | 158 | 2015-07-21 | 2026-02-18 |
| Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Arsenic Trioxide, Gemtuzumab Ozogamicin, Laboratory Biomarker Analysis - Acute Promyelocytic Leukemia With PML-RARA | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 151 | 2011-10-05 | 2026-05-20 |
| Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis Arsenic Trioxide, Ascorbic Acid, Laboratory Biomarker Analysis - Essential Thrombocythemia, Polycythemia Vera | Phase 1 | Terminated | Roswell Park Cancer Institute | 5 | 2010-04-01 | 2022-07-22 |
| Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Arsenic Trioxide, Cytarabine, Diagnostic Laboratory Biomarker Analysis - Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm | Phase 3 | Completed | Children's Oncology Group | 106 | 2009-03-09 | 2022-10-25 |
| Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy Disulfiram, Arsenic trioxide - Metastatic Melanoma | Phase 1 | Terminated | University of California, Irvine | 9 | 2006-09-01 | 2019-08-07 |
Breast Neoplasms (1) · Carcinoma, Basal Cell (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Promyelocytic, Acute (1) · Melanoma (1) · Myelodysplastic Syndromes (1) · Polycythemia Vera (1) · Primary Myelofibrosis (1) · Thrombocythemia, Essential (1)
Children's Oncology Group (2) · Jean Yuh Tang (1) · M.D. Anderson Cancer Center (1) · Roswell Park Cancer Institute (1) · Sun Yat-sen University (1) · University of California, Irvine (1) · University of Michigan Rogel Cancer Center (1)
United States (6) · Canada (2) · Puerto Rico (2) · Australia (1) · China (1) · New Zealand (1) · Saudi Arabia (1)
Eunice Wang, MD (1) · Farhad Ravandi-Kashani (1) · Jean Tang (1) · John J Gregory (1) · John M Magenau (1) · John P Fruehauf, M.D. PhD (1) · Matthew A Kutny (1)
U10CA098543 (1), U10CA180886 (1)